IL129592A0 - 5-HT1f agonists - Google Patents
5-HT1f agonistsInfo
- Publication number
- IL129592A0 IL129592A0 IL12959297A IL12959297A IL129592A0 IL 129592 A0 IL129592 A0 IL 129592A0 IL 12959297 A IL12959297 A IL 12959297A IL 12959297 A IL12959297 A IL 12959297A IL 129592 A0 IL129592 A0 IL 129592A0
- Authority
- IL
- Israel
- Prior art keywords
- ht1f
- formula
- agonists
- compounds
- ht1f agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 102100036311 5-hydroxytryptamine receptor 1F Human genes 0.000 abstract 2
- 101710138086 5-hydroxytryptamine receptor 1F Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electroluminescent Light Sources (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3095096P | 1996-11-15 | 1996-11-15 | |
| PCT/US1997/020630 WO1998020875A1 (en) | 1996-11-15 | 1997-11-13 | 5-ht1f agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL129592A0 true IL129592A0 (en) | 2000-02-29 |
Family
ID=21856862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12959297A IL129592A0 (en) | 1996-11-15 | 1997-11-13 | 5-HT1f agonists |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US5817671A (enExample) |
| EP (1) | EP0842934B1 (enExample) |
| JP (1) | JP2001503774A (enExample) |
| AT (1) | ATE253063T1 (enExample) |
| AU (1) | AU5435298A (enExample) |
| CA (1) | CA2271272A1 (enExample) |
| CO (1) | CO4910133A1 (enExample) |
| DE (1) | DE69725825T2 (enExample) |
| DK (1) | DK0842934T3 (enExample) |
| ES (1) | ES2210463T3 (enExample) |
| ID (1) | ID18883A (enExample) |
| IL (1) | IL129592A0 (enExample) |
| NO (1) | NO991974L (enExample) |
| PE (1) | PE14199A1 (enExample) |
| PT (1) | PT842934E (enExample) |
| WO (1) | WO1998020875A1 (enExample) |
| ZA (1) | ZA979961B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5905084A (en) * | 1997-11-14 | 1999-05-18 | Eli Lilly And Company | 5-HTIF -agonists effective in treating migraine |
| ZA989389B (en) * | 1997-11-14 | 2000-04-14 | Lilly Co Eli | Pyrrolo [3,2-b] pyridine processes and intermediates. |
| US6133290A (en) * | 1998-07-31 | 2000-10-17 | Eli Lilly And Company | 5-HT1F agonists |
| GB9823845D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
| WO2000034266A1 (en) * | 1998-12-11 | 2000-06-15 | Eli Lilly And Company | Indole derivatives and their use as 5-ht1f agonists |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
| TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| ES2201899B1 (es) * | 2002-04-01 | 2005-06-01 | Almirall Prodesfarma, S.A. | Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos. |
| JP2006523692A (ja) | 2003-04-18 | 2006-10-19 | イーライ リリー アンド カンパニー | ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物 |
| UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| AU2004293026B2 (en) * | 2003-11-21 | 2012-01-19 | Array Biopharma Inc. | AKT protein kinase inhibitors |
| EP1697305B1 (en) | 2003-12-17 | 2007-08-15 | Eli Lilly And Company | Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists |
| RU2481336C2 (ru) | 2006-07-06 | 2013-05-10 | Эррэй Биофарма Инк. | Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт |
| DE602007011628D1 (de) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren |
| WO2008006039A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| MX2009014013A (es) * | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| CA2692502C (en) | 2007-07-05 | 2016-03-01 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US8853216B2 (en) * | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| US8835434B2 (en) * | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| JP5727457B2 (ja) | 2009-04-02 | 2015-06-03 | コルーシッド ファーマシューティカルズ， インコーポレイテッド | ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物 |
| US8697876B2 (en) | 2010-04-02 | 2014-04-15 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| FI2694072T4 (fi) | 2011-04-01 | 2024-09-30 | Genentech Inc | Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa |
| BG111544A (bg) | 2013-07-29 | 2015-01-30 | Николай Цветков | Субституирани бензамидни производни като in vitro mao-b инхибитори |
| CU24398B1 (es) * | 2013-08-02 | 2019-04-04 | Pfizer | 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2 |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| WO2017141116A1 (en) * | 2016-02-19 | 2017-08-24 | Phoenix Molecular Designs | Carboxamide derivatives useful as rsk inhibitors |
| US11858910B2 (en) | 2018-08-24 | 2024-01-02 | Sunshine Lake Pharma Co., Ltd. | Pyridinylmethylenepiperidine derivatives and uses thereof |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| US12378245B2 (en) | 2019-02-11 | 2025-08-05 | Phoenix Molecular Designs | Crystalline forms of an RSK inhibitor |
| AR119319A1 (es) | 2019-07-09 | 2021-12-09 | Lilly Co Eli | Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3080374A (en) * | 1962-02-08 | 1963-03-05 | Abbott Lab | 2-guanidino-3-nitropyridine and derivatives thereof |
| WO1990007926A1 (en) * | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
| US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
| US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| KR19980703048A (ko) * | 1995-03-20 | 1998-09-05 | 피터쥐.스트링거 | 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트 |
-
1997
- 1997-11-05 ZA ZA979961A patent/ZA979961B/xx unknown
- 1997-11-12 DE DE69725825T patent/DE69725825T2/de not_active Expired - Fee Related
- 1997-11-12 PT PT97309106T patent/PT842934E/pt unknown
- 1997-11-12 ES ES97309106T patent/ES2210463T3/es not_active Expired - Lifetime
- 1997-11-12 DK DK97309106T patent/DK0842934T3/da active
- 1997-11-12 AT AT97309106T patent/ATE253063T1/de not_active IP Right Cessation
- 1997-11-12 EP EP97309106A patent/EP0842934B1/en not_active Expired - Lifetime
- 1997-11-13 WO PCT/US1997/020630 patent/WO1998020875A1/en not_active Ceased
- 1997-11-13 PE PE1997001023A patent/PE14199A1/es not_active Application Discontinuation
- 1997-11-13 CO CO97066711A patent/CO4910133A1/es unknown
- 1997-11-13 IL IL12959297A patent/IL129592A0/xx unknown
- 1997-11-13 JP JP52277798A patent/JP2001503774A/ja not_active Ceased
- 1997-11-13 ID IDP973668A patent/ID18883A/id unknown
- 1997-11-13 AU AU54352/98A patent/AU5435298A/en not_active Abandoned
- 1997-11-13 CA CA002271272A patent/CA2271272A1/en not_active Abandoned
- 1997-11-14 US US08/969,851 patent/US5817671A/en not_active Expired - Fee Related
-
1998
- 1998-07-09 US US09/112,562 patent/US5998622A/en not_active Expired - Fee Related
- 1998-07-09 US US09/112,560 patent/US5919936A/en not_active Expired - Fee Related
-
1999
- 1999-04-26 NO NO991974A patent/NO991974L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ID18883A (id) | 1998-05-20 |
| PT842934E (pt) | 2004-03-31 |
| AU5435298A (en) | 1998-06-03 |
| EP0842934A1 (en) | 1998-05-20 |
| CO4910133A1 (es) | 2000-04-24 |
| NO991974D0 (no) | 1999-04-26 |
| DE69725825D1 (de) | 2003-12-04 |
| US5919936A (en) | 1999-07-06 |
| ES2210463T3 (es) | 2004-07-01 |
| ZA979961B (en) | 1999-05-05 |
| JP2001503774A (ja) | 2001-03-21 |
| PE14199A1 (es) | 1999-02-12 |
| WO1998020875A1 (en) | 1998-05-22 |
| EP0842934B1 (en) | 2003-10-29 |
| US5817671A (en) | 1998-10-06 |
| US5998622A (en) | 1999-12-07 |
| DK0842934T3 (da) | 2004-03-08 |
| NO991974L (no) | 1999-04-26 |
| DE69725825T2 (de) | 2004-08-12 |
| ATE253063T1 (de) | 2003-11-15 |
| CA2271272A1 (en) | 1998-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA979961B (en) | 5-HT1F agonists | |
| TW269678B (enExample) | ||
| ES2194960T3 (es) | N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f. | |
| IL148079A0 (en) | Human ctla-4 antibodies and compositions containing the same | |
| ATE168992T1 (de) | 7-substituierte-9-substituierte glycylamido-6- demethyl-6-deoxytetracycline | |
| HU9402342D0 (en) | Phosphono-oxymethyl-ethers of taxane derivatives | |
| CY2543B1 (en) | 9-Ä(Substituted glycyl)amidoÜ-6-(substituted)-5-hydroxy-6-deoxytetracyclines | |
| BG105270A (en) | Tetrahydropyridoethers | |
| DE69331774D1 (de) | 7-Substituierte-8-substituierte-9-substituierte Amino-7-Demethyl-6-Deoxy-Tetracycline als antibiotische Mittel | |
| IL142900A0 (en) | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer | |
| BG105256A (en) | Muscarinic agonists and antagonists | |
| IL133279A0 (en) | Carboxamides useful as 5-ht1f agonists | |
| SE9802937D0 (sv) | Novel compounds | |
| BR9807883A (pt) | Compostos de tetraidropirido | |
| PL340459A1 (en) | Agonists of 5ht1f | |
| BG105539A (bg) | Елетриптан хидробромид монохидрат | |
| GB9302046D0 (en) | Antiumoral compound-v | |
| BG107553A (en) | Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same | |
| DE69929802D1 (en) | Lta4 hydrolase-hemmer | |
| BG105549A (en) | Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system | |
| TWI231815B (en) | Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents | |
| PE61999A1 (es) | Compuestos de tetrahidropiridina | |
| ID27964A (id) | Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya |